This is a compassionate use protocol allowing sarcoma patients that have relapsed after prior therapies and are not eligible for other protocols involving the evaluation of aldoxorubicin to receive aldoxorubicin.
Compassionate use of aldoxorubicin in sarcoma patients who have failed prior chemotherapy.